Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Harvard Business School
Colorcon
Boehringer Ingelheim
Baxter

Last Updated: March 24, 2023

Drugs with Dosage: PELLETS


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Drugs with Dosage: PELLETS

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration Dosage
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate PELLETS;ORAL 214358-001 Jun 21, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing PELLETS;ORAL
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate PELLETS;ORAL 214358-001 Jun 21, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing PELLETS;ORAL
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate PELLETS;ORAL 214358-001 Jun 21, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing PELLETS;ORAL
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate PELLETS;ORAL 214358-001 Jun 21, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing PELLETS;ORAL
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate PELLETS;ORAL 214358-001 Jun 21, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing PELLETS;ORAL
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate PELLETS;ORAL 214358-002 Jun 21, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing PELLETS;ORAL
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration >Dosage

Subscribe to access the full database, or Try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Merck
Dow
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2023 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2023 - 2024
 NCE-1 Patent Challenge Dates 2023 - 2024
 ClinicalTrialExchange - Connecting volunteers and trials
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group